Pakistan's minister in charge of drug pricing confirmed at a news conference a new policy would reduce the costs of some drugs by as much as 30%, but said no changes would become effective before June 30, 2016.
India authorities placed a 5-year ban on Kivi Labs for submitting any filings with the Central Drugs Standards Control Organization after determining the company filed fictitious and forged documents for fixed-dosage combinations.
India health authorities have threatened to close pharmacies in the country that fail to maintain an adequate supply of Tamiflu (oseltamivir) or its generics to treat an outbreak of H1N1 influenza.
The Indian government is expected to announce new strategies to bolster its bulk drug manufacturing capacity as part of an effort to reduce the country's dependency on Chinese API imports.
"One of the biggest surprises people are going to have when they start using it is the breadth of what it will do," Apple CEO Tim Cook recently said about the upcoming Apple Watch. Too bad the smartwatch's functionalities won't include stress monitors, an electrocardiogram or a blood pressure monitor.
New drug approvals were up last year, and orphan drug approvals were no exception. But by just how much did they climb? The FDA Law Blog has done some digging through the agency's Orphan Drug Designations and Approvals database, and it's got an answer.
The FDA accepted Apotex's application to copy an Amgen blockbuster, giving the Canadian drugmaker a chance to cash in on the coming biosimilar boom in the U.S.
Pharma bigwig Pfizer announced that the FDA has agreed to review the New Drug Application of its abuse-deterring extended-release opioid capsules, dubbed ALO-02.
Eisai won speedy FDA approval for its new cancer drug Lenvima, eyeing $1 billion in potential sales and setting the stage for a showdown with Bayer's cancer-fighter Nexavar.
Sprout Pharmaceuticals is heading back to the FDA with a twice-rejected treatment for female sexual dysfunction, betting that its follow-on studies will be enough to finally convince the agency.